In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Kodiak Sciences (KOD – Research Report), with a price target of $20.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Yee has given his Buy rating due to a combination of factors that suggest a promising outlook for Kodiak Sciences. The company is preparing for a significant R&D day in June, where it will present new data for its IL6 x VEGF bispecific drug, KSI-101. This event is expected to generate positive momentum as the stock is currently undervalued, trading just above cash levels, with major Phase III data anticipated in the first half of 2026.
Furthermore, Kodiak Sciences’ strategic plans include advancing KSI-101 into Phase III trials, with agreements already in place with the FDA regarding trial design. The company is also on track with its Phase III trials for other formulations, which are expected to yield results in 2026. With a solid cash position to support these initiatives and potential financial strategies to bolster resources, Yee sees a strong potential for stock appreciation as these developments unfold.
KOD’s price has also changed moderately for the past six months – from $2.660 to $3.060, which is a 15.04% increase.